Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.

Nature communications - 19 Jan 2017

Tagal Vural, Wei Shuguang, Zhang Wei, Brekken Rolf A, Posner Bruce A, Peyton Michael, Girard Luc, Hwang TaeHyun, Wheeler David A, Minna John D, White Michael A, Gazdar Adi F, Roth Michael G

Abstract excerpt

Mutations in the SMARCA4/BRG1 gene resulting in complete loss of its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells. Currently, no single therapeutic agent has been identified as synthetically lethal with SMARCA4/BRG1 loss. We identify AURKA activity as essential in NSCLC cells lacking SMARCA4/BRG1. In these cells, RNAi-mediated depletion or chemical inhibition of AURKA induces...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Helicases

Share to Mice, SCID

Share to Neoplasms, Experimental

Share to Piperazines

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 28102363
DOI: 10.1038/ncomms14098
PMCID: PMC5253647

Genes

SMARCA4
AURKA
DLGAP5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.PMID 28102363Read ↗

High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancerSemantic proximity Read ↗

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.Semantic proximity Read ↗

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.Semantic proximity Read ↗

SMARCA4/BRG1–Deficient Non–Small Cell Lung Carcinomas: A Case Series and Review of the LiteratureSemantic proximity Read ↗

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for CancerSemantic proximity Read ↗

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneSemantic proximity Read ↗

Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cellsSemantic proximity Read ↗

RNA Interference Targeting Aurora Kinase A Suppresses Tumor Growth and Enhances the Taxane Chemosensitivity in Human Pancreatic Cancer CellsSemantic proximity Read ↗

BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin OrganizationSemantic proximity Read ↗

Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human RetinoblastomaSemantic proximity Read ↗

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockadeSemantic proximity Read ↗

The Ipl1/Aurora kinase family: methods of inhibition and functional analysis in mammalian cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.